Results 41 to 50 of about 15,266 (342)

Defining Priorities to Improve Patient Experience in Non-Muscle Invasive Bladder Cancer [PDF]

, 2018
Although approximately 75% of bladder cancers are non-muscle invasive (NMIBC) at diagnosis, most research tends to focus on invasive disease (e.g., experiences related to radical cystectomy and urinary diversion). There is a lack of studies on quality of
Bogaczyk, Tyler L., Connors, Jill Nault, Garg, Tullika, Ladd, Ilene G., Larson, Sharon L.   +4 more
core   +2 more sources

Complete en bloc urinary exenteration for synchronous multicentric transitional cell carcinoma with sarcomatoid features in a hemodialysis patient

International Brazilian Journal of Urology, 2006
The incidence of transitional cell carcinoma (TCC) in patients submitted to hemodialysis is low. The presence of TCC with sarcomatoid features in this cohort is even scarcer.
Tiberio M. Siqueira Jr, Evandro Falcao, Tiberio M. Siqueira   +2 more
doaj   +1 more source

A case of primary renal oncocytic tumor: Chromophobe renal cell carcinoma or oncocytoma?

IJU Case Reports, 2023
Introduction “Other oncocytic renal tumors of the kidney” is a new category constituted by 2022 WHO classification and different in the point of morphology and immunohistochemistory from typical oncocytic/eosinophilic renal tumors including chromophobe ...
Kenta Matsui, Katsunori Uchida, Masahiro Kanai, Kana Asakawa, Miki Usui, Tetsuya Murata   +5 more
doaj   +1 more source

Primary apocrine adenocarcinoma of scrotum suspected as urothelial carcinoma metastasis: A clinical and pathological dilemma

Urology Annals, 2015
A 78-year-old man presented with an enlarging, tender mass in the scrotum separate to the testes. This was on the background of radical cystoprostatectomy, urethrectomy, and ileal conduit formation for high-grade urothelial carcinoma of the bladder ...
Sean Huang, Mark Frydenberg, Alan Pham, Jeremy P Grummet   +3 more
doaj   +1 more source

The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers [PDF]

, 2015
Objective: To evaluate the additive value of the prostate cancer gene 3 (PCA3) urine test to serum prostate-specific antigen (PSA) in prostate cancer (PC) screening among breast cancer, early-onset gene (BRCA) mutation carriers.
Aaronson, N.K. (Neil), Ardem-Jones, A., Asperen, C.J. (Christi) van, Bancroft, E.K. (Elizabeth), Bancroft, E.K. (Elizabeth), Bangma, C.H. (Chris), Castro, E. (Elena), Cremers, R.G.H.M. (Ruben), Dearnaley, D. (David), Eccles, D. (Diana), Eeles, R. (Rosalind), Eeles, R. (Rosalind), Evans, D.G. (Gareth), Eyfjord, J., Falconer, A., Foster, C.S. (Christopher), Grönberg, H. (Henrik), Hamdy, F. (Freddie), Johansson, O., Khoo, V., Kiemeney, L.A.L.M. (Bart), Kote-Jarai, Z., Lilja, H. (Hans), Lubinski, J. (Jan), Maehle, L., Melia, J., Mikropoulos, C., Mitchell, G. (Gillian), Mitra, A. (Anita), Moss, S.M. (Sue), Moynihan, C., Page, E. (Elizabeth), Rennert, G. (Gad), Ringelberg-Borsboom, J. (Janneke), Schalken, J.A. (Jack), Suri, M. (Mohnish), Vasen, H. (Hans), Verhaegh, G. (Gerald), Wilson, P.   +38 more
core   +1 more source

Targeting carbonic anhydrase IX/XII prevents the anti‐ferroptotic effect of stromal lactic acid in prostate carcinoma

Molecular Oncology, EarlyView.
In prostate carcinoma, lactic acid, secreted by highly glycolytic cancer‐associated fibroblasts, is imported into tumor cells through the MCT1 transporter and prevents RSL3 and erastin‐induced ferroptosis (A). Targeting of carbonic anhydrase IX/XII, the main extracellular pH regulators, in tumor and stromal cells reduces microenvironmental acidosis and
Elisa Pardella, Giuseppina Comito, Luigi Ippolito, Erica Pranzini, Marta Iozzo, Giulia Gangarossa, Francesca Virgilio, Silvia Bua, Alessio Nocentini, Giada Sandrini, Nicla Lorito, Marina Bacci, Gabriella Nesi, Pietro Spatafora, Sergio Serni, Claudiu T. Supuran, Andrea Morandi, Paola Chiarugi, Elisa Giannoni   +18 more
wiley   +1 more source

Is moderate hypofractionation accepted as a new standard of care in north america for prostate cancer patients treated with external beam radiotherapy? Survey of genitourinary expert radiation oncologists [PDF]

, 2019
INTRODUCTION: Several recent randomized clinical trials have evaluated hypofractionated regimens against conventionally fractionated EBRT and shown similar effectiveness with conflicting toxicity results.
Chen, Yiyi, Degnin, Catherine, Hung, Arthur Y., McClelland, Shearwood, Mitin, Timur, Sandler, Kiri A.   +5 more
core   +1 more source

Single‐cell transcriptomics redefines focal neuroendocrine differentiation as a distinct prostate cancer pathology

Molecular Oncology, EarlyView.
Single‐cell transcriptomics of prostate cancer patient‐derived xenografts reveals distinct features of neuroendocrine (NE) subtypes. Tumours with focal NE differentiation (NED) share transcriptional programmes with adenocarcinoma, differing from large and small cell neuroendocrine prostate cancer (NEPC). Our work defines the molecular landscape of NEPC,
Rosalia Quezada Urban, Shivakumar Keerthikumar, Ashlee Clark, Hong Wang, Belinda Phipson, Andrew Bakshi, Andrew Ryan, Heather Thorne, Renea A. Taylor, Mitchell G. Lawrence, Gail P. Risbridger, Roxanne Toivanen, David L. Goode   +12 more
wiley   +1 more source

Artificial intelligence algorithm for neoplastic cell percentage estimation and its application to copy number variation in urinary tract cancer [PDF]

Journal of Pathology and Translational Medicine
Background Bladder cancer is characterized by frequent mutations, which provide potential therapeutic targets for most patients. The effectiveness of emerging personalized therapies depends on an accurate molecular diagnosis, for which the accurate ...
Jinahn Jeong, Deokhoon Kim, Yeon-Mi Ryu, Ja-Min Park, Sun Young Yoon, Bokyung Ahn, Gi Hwan Kim, Se Un Jeong, Hyun-Jung Sung, Yong Il Lee, Sang-Yeob Kim, Yong Mee Cho   +11 more
doaj   +1 more source

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source